Flucelvax Tetra Injektionssuspension

Maa: Sveitsi

Kieli: saksa

Lähde: Swissmedic (Swiss Agency for Therapeutic Products)

Aktiivinen ainesosa:

haemagglutininum influenzae A (H3N2) (Virus Stamm A/Kansas/14/2017 (H3N2)-like: derived from A/Indiana/08/2018), haemagglutininum influenzae A (H1N1) (Virus Stamm A/Brisbane/02/2018 (H1N1)-like: derived from A/Idaho/07/2018), haemagglutininum influenzae B (Virus Stamm B/Colorado/06/2017-like: reassortant from B/Iowa/06/2017 (Victoria lineage))

Saatavilla:

Vifor (International) Inc.

ATC-koodi:

J07BB02

INN (Kansainvälinen yleisnimi):

haemagglutininum influenzae A (H3N2) (Virus Stamm A/Kansas/14/2017 (H3N2)-like: derived from A/Indiana/08/2018), haemagglutininum influenzae A (H1N1) (Virus Stamm A/Brisbane/02/2018 (H1N1)-like: derived from A/Idaho/07/2018), haemagglutininum influenzae B (Virus Stamm B/Colorado/06/2017-like: reassortant from B/Iowa/06/2017 (Victoria lineage))

Lääkemuoto:

Injektionssuspension

Koostumus:

haemagglutininum influenzae A (H3N2) (Virus Stamm A/Kansas/14/2017 (H3N2)-like: derived from A/Indiana/08/2018) 15 µg, haemagglutininum influenzae A (H1N1) (Virus Stamm A/Brisbane/02/2018 (H1N1)-like: derived from A/Idaho/07/2018) 15 µg, haemagglutininum influenzae B (Virus Stamm B/Colorado/06/2017-like: reassortant from B/Iowa/06/2017 (Victoria lineage)) 15 µg, haemagglutininum influenzae B (Virus Stamm B/Phuket/3073/2013-like: reassortant from B/Singapore/INFTT-16-0610/2016 (Yamagata lineage)) 15 µg, natrii chloridum, kalii chloridum, magnesii chloridum hexahydricum, natrii dihydrogenophosphas dihydricus, kalii dihydrogenophosphas, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml corresp. natrium 1.7 mg, kalium 0.1 mg, residui: polysorbatum 80, cetrimidum, propiolactonum.

luokka:

B

Terapeuttinen ryhmä:

Impfstoffe

Terapeuttinen alue:

aktive Immunisierung gegen Influenza , ab 9 Jahren

Valtuutuksen tilan:

zugelassen

Valtuutus päivämäärä:

2021-04-05